IMDC
@IMDConline
Followers
239
Following
67
Media
4
Statuses
134
International mRCC Database Consortium #IMDC #kcsm
Joined December 2019
RT @ZiadBakouny: Post-call in the CCU, so late in sharing this but thrilled to see our work on upfront cytoreductive nephrectomy in metasta….
0
6
0
RT @DrChoueiri: JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The @I….
0
100
0
RT @anobelodisho: Using nomograms in the real world is tricky and hides clinical variation. We built an interactive viz for #kidneycancer o….
0
19
0
RT @montypal: Phenomenal work from @anobelodisho collaborating with @IMDConline @DrChoueiri @DrDanielHeng @gorejohn - this will be a useful….
0
2
0
RT @ChunLGan: Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Imm….
0
34
0
RT @DrDanielHeng: Alberta Immunotherapy Database-led study shows pts that are trial ineligible by common criteria have poorer associated ou….
0
9
0
Congratulations @DrJeffreyGraham!!.
This month’s @EurUrolOncol #SoMe Award is presented to…. Outcomes of Patients with Metastatic RCC Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Congrats to @DrJeffreyGraham, Amishi Y. Shah & coauthors!. #kidneycancer
0
0
5
RT @montypal: For my colleagues in #GeriOnc, nice article led by @DVAraujoMD & @ShaanDudani looking at age & outcome w ICIs in #kidneycanc….
0
15
0
RT @montypal: Woderful work by @lalaniMD using the @IMDConline database w @DrDanielHeng @DrChoueiri et al! The IMDC is a gift that keeps on….
0
7
0
RT @ZiadBakouny: Thrilled to see our paper out in @JAMAOnc!.@lalaniMD @DrChoueiri @DrDanielHeng @ShaanDudani.@FDonskov @IMDConline. The IO….
0
7
0
RT @lalaniMD: As always, thanks to important contributions by international investigators, sites, and *most importantly* patients to team e….
0
3
0
RT @dr_aschmidt: 4/ Looking at all patients with mRCC, incorporating the very favorable category into IMDC criteria, we can identify 4 dist….
0
2
0
RT @DrYukselUrun: Outcomes of 1st line combos in inter/poor-risk mRCC from @IMDConline @ChunLGan .🔶Higher ORR, lower PD with IO-VEGF/TKI.🔶S….
0
10
0
RT @dr_aschmidt: RCC has diverse outcomes: proud to be part of work @ASCO #GU21 from @DrChoueiri @DrDanielHeng @IMDConline where we identif….
0
8
0
RT @DrChoueiri: Now with @ChunLGan @IMDConline with real-word evidence showing equivalent OS and TTNT between IO-IO and IO-VEGF regimens in….
0
10
0
RT @DrJeffreyGraham: Our @IMDConline analysis on the effectiveness of first-line ICI based therapy in advanced non-clear cell RCC!.@DrDanie….
0
10
0
RT @KrgerMd: @DrDanielHeng @ShaanDudani @OncoAlert @OncEd @JAMANetworkOpen @JAMAOnc Congrats @ShaanDudani and @DrDanielHeng for this import….
0
1
0
RT @ShaanDudani: Just out in @JAMANetworkOpen: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all @IMD….
0
58
0
RT @JAMANetworkOpen: Cohort study finds metastases vary between histologic subtypes of mRCC, sites of metastatic involvement are associated….
0
10
0